What are the indications, recommended regimen, and safety considerations for plasmapheresis in patients with severe acute or autoimmune hepatitis?

Plasmapheresis in Hepatitis: Limited Role, Not Standard Therapy

Plasmapheresis is NOT a standard or recommended treatment for autoimmune hepatitis or acute liver failure from hepatitis, and current guidelines do not support its routine use. The only specific indication where plasmapheresis may be considered in hepatitis-related conditions is for Wilson disease presenting with acute liver failure, where it serves to acutely lower serum copper levels 1.

Standard Treatment for Autoimmune Hepatitis

First-Line Therapy

• High-dose corticosteroids are the established treatment for autoimmune hepatitis, including acute severe presentations 1
• Predniso(lo)ne starting at 40-60 mg/day is recommended for acute liver failure due to autoimmune hepatitis 1
• For acute severe autoimmune hepatitis, intravenous corticosteroids ≥1 mg/kg should be initiated as early as possible, ideally before hepatic encephalopathy onset 1
• Budesonide (9 mg/day) plus azathioprine may be used in treatment-naive non-cirrhotic patients 1

When Corticosteroids Fail

• Patients should be listed for liver transplantation if no improvement occurs within 7-14 days of corticosteroid therapy 1
• Patients with severe coagulopathy and hepatic encephalopathy grade III-IV should proceed directly to transplant evaluation rather than corticosteroid trial 1

Why Plasmapheresis Is Not Recommended

Lack of Guideline Support

• No major hepatology guidelines (EASL, AASLD, BSG) recommend plasmapheresis for autoimmune hepatitis or viral hepatitis 1
• The evidence base consists only of isolated case reports and small case series from the 1980s-1990s, which lack the quality to change practice 2, 3, 4

Limited Evidence Base

• One case report from 1993 described plasmapheresis in a single patient with AIH-SLE overlap who was steroid-refractory 2
• Historical reports from the 1980s examined plasmapheresis in acute liver failure from various causes, with mixed results and no controlled data 3, 4
• A 2021 study showed benefit in hepatitis B exacerbations, but this does not translate to autoimmune hepatitis 5

The Only Exception: Wilson Disease

Plasmapheresis, plasma exchange, or continuous hemofiltration should be considered in Wilson disease presenting with acute liver failure to acutely lower serum copper and limit hemolysis 1. However:

• Recovery is infrequent without transplantation even with these measures 1
• Penicillamine should NOT be initiated in acute liver failure due to hypersensitivity risk 1
• Direct plasma copper reduction is more effective than chelation therapy in this acute setting 1

Clinical Algorithm for Severe Hepatitis

For Acute Severe Autoimmune Hepatitis:

1. Initiate high-dose IV corticosteroids (≥1 mg/kg) immediately if hepatic encephalopathy is absent or grade I-II 1
2. Contact transplant center simultaneously for evaluation 1
3. Assess response at 7 days: Look for improvement in INR, bilirubin, and liver biochemistry 1
4. If no improvement or worsening by 7-14 days: List for emergency liver transplantation 1
5. If hepatic encephalopathy grade III-IV at presentation: Proceed directly to transplant evaluation without corticosteroid trial 1

For Chronic Autoimmune Hepatitis:

• Standard therapy is predniso(lo)ne followed by addition of azathioprine after 2 weeks 1
• Treatment should continue for at least 2 years and for at least 12 months after transaminase normalization 1
• Second-line options include mycophenolate mofetil or tacrolimus for steroid-refractory cases 1

Important Caveats

• Plasmapheresis carries significant risks including vascular access complications, coagulation abnormalities, hypocalcemia, allergic reactions to replacement fluids, and infection 6
• In patients with severe coagulopathy and thrombocytopenia (common in acute liver failure), plasmapheresis poses additional hemorrhagic risks 4
• The pathophysiology of autoimmune hepatitis involves T-cell mediated hepatocyte destruction, not primarily circulating antibodies, making antibody removal theoretically less effective 1
• Supportive care and consideration for liver transplantation remain the cornerstones of management for acute liver failure from any cause 1